title: Interleukin-2 treatment of tumor patients can expand regulatory T cells.
abstract: Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.
authors.affiliation: Genomics and Immunoregulation; LIMES-Institute; University of Bonn; Bonn, Germany.
authors.forename: Marc
authors.initials: M
authors.lastname: Beyer